Neko Health, the preventive health technology company founded by Spotify co-founder Daniel Ek and Hjalmar Nilsonne, has raised $700 million in a Series C funding round as it prepares to open its first U.S. clinics in New York and other cities this year.
The round was led by Lightspeed Venture Partners and co-led by O.G. Venture Partners, with participation from existing investors Atomico, General Catalyst and Lakestar. New backers included Liberty City Ventures, Positive Sum and BDT & MSD. The raise follows a $260 million Series B round in January 2025.
Neko Health body scan
(Photo: Neko Health)
As part of the financing, David Ofer of O.G. Venture Partners is expected to join Neko Health’s board of directors, subject to regulatory approval.
Founded in Sweden, Neko Health offers a 60-minute preventive health scan that combines proprietary sensors, blood analysis and an in-person consultation with a clinician. The company says the scan captures millions of health data points and is designed to help detect early signs of disease before symptoms appear. The service costs 299 pounds in the UK and 2,750 Swedish kronor in Sweden.
The company said more than 350,000 people have joined its waitlist or registered for a scan, while more than 100,000 people in the UK and Sweden have already completed one. At the end of their first appointment, Neko said, 75% of members book and prepay for their next scan.
The funding will support Neko’s expansion into the United States and continued investment in its technology, including hardware, software and the customer experience. The company builds much of its technology in-house, a vertically integrated model it says allows it to control the experience from start to finish and roll out improvements more quickly.
“This funding is a strong vote of confidence in what we set out to do when we opened our first clinic three years ago: a completely new healthcare experience designed to keep people healthy, catch problems early and help prevent disease before it even starts,” Nilsonne, Neko Health’s co-founder and CEO, said.
“With this round, we’re taking that mission to the U.S. for the first time, while continuing to invest in the research and technology that make prevention possible at scale,” he added. “The clearest proof is in our members: the vast majority of our members return after their first scan, and when they do, their health markers move in the right direction.”
Neko said its scans assess skin health, including moles and marks, as well as biomarkers linked to prediabetes, blood abnormalities, metabolic syndrome, stroke and heart attack risk. Results are delivered within minutes and reviewed with a medical professional during the same visit.
The company recently added body composition analysis and clinician review of wearable data across all its clinics. It also opened a new clinic in Stockholm built around updated medical devices developed by Neko, including Derma-2, Echo-2 and Spectrum-2, which the company says capture more detailed signals related to skin, heart and circulation. The upgraded devices are expected to be introduced across all Neko clinics in the coming months.
Neko has expanded since its launch in February 2023, opening locations in Sweden and the UK, including Manchester, Birmingham and several sites in London, among them Marylebone, Spitalfields, Covent Garden and Victoria.
The company says early detection is beginning to translate into measurable health improvements among returning members. According to Neko’s latest data, three in four returning members who previously had severe or life-threatening conditions identified were either in good health or had their condition under control by their next scan. The company also said five of seven key biomarkers showed statistically significant improvement between a member’s first and second scans.
Investors framed the raise as a bet on the growing market for preventive health care, as health systems, employers and consumers focus more attention on early detection and chronic disease prevention.
“Over the past eighteen months, Neko Health has demonstrated remarkable innovation and growth, attacking one of the largest markets in the world with breakthrough technology, proven consumer demand, and a clear path to global scale,” said Bejul Somaia, global partner at Lightspeed Venture Partners. “We believe this is one of the most important healthcare companies of our generation, and we’re proud to deepen our partnership as they continue to reimagine prevention.”
The round also included a number of high-profile individual investors, among them Ari Emanuel, Claudia Schiffer, Sir Matthew Vaughn, Danny Meyer, Jimmy Iovine, Maria Sharapova, Mark Zuckerberg and Priscilla Chan, Thierry Henry, Tim Ferriss and will.i.am. Existing individual backers include Alexis Ohanian of Seven Seven Six, Gary Vaynerchuk, Katie Haun, Steven Bartlett, Zoë Saldaña and Marco Perego-Saldaña.
Ferriss, the author of “The 4-Hour Body,” said he invested because Neko simplifies what is often an expensive and fragmented process.
“For more than 20 years, I’ve tracked every metric imaginable to optimize health and performance,” Ferriss said. “It’s expensive, complicated and fragmented. I’ve invested in Neko because they offer beautiful simplicity, and only simplicity scales: you get a high-definition map of your biology in less than 60 minutes, explained by an unhurried doctor, all in one location and for £299. No one else can do this.”
Neko’s U.S. launch will test whether its consumer-focused preventive care model can scale in a far larger and more fragmented health market. The company is entering as demand grows for tools that can identify chronic disease risks earlier, but also as questions remain over access, affordability and how such services fit alongside traditional primary care.
